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Abstract
Echinococcosis is caused by infection with larva (metacestode) of the tapeworms of the 
genus Echinococcus. Within genus Echinococcus, two species are known as public health 
concern worldwide: Echinococcus guanulosus causing cystic echinococcosis (CE) and 
Echinococcus multilocularis causing alveolar echinococcosis (AE). The co-evaluation due to 
the interaction between parasites and their hosts has been well known to be able to allow 
tolerating to maintain parasitism as long as possible. With many research advanced find-
ings, scientists have been much interested in using either those molecules from parasites 
producing due to invading and surviving or those cytokines from hosts responding due 
to defenses to carry out immunotherapeutic practice that is not only against parasitic 
infection but also for cancer or other immunological related disorders. Taken advance of 
knowledge on Echinococcus genome research outcomes, recent attentions regarding the 
discoveries of targeting antiparasitic drug and/or vaccine were extensively discussed in 
this review.
Keywords: Echinococcus species, parasitism, interactions between parasites and hosts, 
immunotherapy agents, drug and vaccine discoveries
1. Introduction
The echinococcosis in human occurs as a result of infection by the larval stages of taeniid ces-
todes of the genus Echinococcus. Originally, four species have been recognized as the public 
health concern: Echinococcus granulosus [agent of cystic echinocococcosis (CE)], Echinococcus 
multilocularis [agent of alveolar echinococcosis (AE)], and Echinococcus vogeli and Echinococcus 
oligarthrus [both are the agents of polycystic echinococcosis (PE)] [1]. Recently, two new spe-
cies have been identified: Echinococcus shiquicus [2] in small mammals from the Tibetan pla-
teau and Echinococcus felidis [3] in African lions though these two new species infective to 
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human are still unknown [4]. A couple of studies have provided augments that these diseases 
are an increasing public health concern and showing emerging or re-emerging diseases [4, 5].
Among recognized four public health concerned species, E. multilocularis and E. granulosus 
are important for human health and economic welfare [4]. The disease occurs in most areas 
of the world, and currently about 4 million people are infected and another 40 million people 
are at risk [4, 6, 7]. The economic cost of the disease is estimated to be around 3 billion USD a 
year. It is classified as a neglected tropical disease [4].
The knowledge on the geographical distribution of the environmental factors for the persistence 
of the lifecycle is scarce [8, 9]. Studies to improve the knowledge on epidemiological risk factors 
should be encouraged to enable risk-based sampling. Echinococcus notification should always 
be done at species level in order to discriminate between the more severe alveolar and the cystic 
echinococcosis [10, 11]. Updated knowledge on the Echinococcus parasitism was also discussed for 
the potential application in immunotherapeutic against parasites and other immune disorders.
2. Transmission
The life cycle of Echinococcus species requires a predator-prey relationship between the defini-
tive and intermediate hosts.
E. granulosus is adapted to an environment in which livestock farming plays a central role, com-
pleting its cycle through dogs or wild carnivorous animals (as definitive host) and a variety 
of livestock species, mainly sheep, cattle, pigs, horses, goats, and camels as well as the several 
wild ungulate species serve as intermediate hosts for the different lineages of the E. granulosus 
species complex [12]. In contrast, several wild rodent species (typically rodents of the families 
Arvicolidae and Cricetidae) are the natural intermediate host for E. multilocularis [12, 13].
The intermediate hosts become infected through ingestion of eggs in contaminated food or 
water [12]. The host digestive enzymes dissolve the egg’s shell, releasing the oncosphere, which 
burrows through the host’s gut wall and is transported via blood or lymph to the target organ of 
liver for AE, but mainly liver and lungs, as well other organs for CE [14]. While the life cycle of E. 
multilocularis is completed after a fox or canine consumes a rodent infected with alveolar echin-
coccosis [8]. Once again adults begin to release a new gravid proglottid, which usually carries 
some 1500 eggs [15], to be passed to the outside environment with their feces. The adult worms 
are hermaphroditic. E. granulosus becomes prepatent in 32–80 days in the definitive hosts [16], 
this period varies with the species or strain. While E. multilocularis usually becomes prepatent in 
foxes or dogs in 28–35 days [17], the life cycle of E. multiloculcaris is predominantly sylvatic [18].
Humans can serve as an aberrant intermediate host, acquiring the infection by accidental 
ingestion of eggs, due to handling of infected animals or ingesting contaminated food, vegeta-
ble, and water. Except in rare cases, where infected humans are eaten by canines [19], humans 
are a deadend for Echinococcus species, which means that this kind of intermediate host does 
not allow transmission to the definitive host [20].
Briefly, the disease is spreading when food or water contains the eggs of the parasite, which may 
be eaten by intermediate animals (such as sheep for E. granulosus and rodents for E. multilocularis), 
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or due to close contact with an infected definitive animal (carnivorous animals, e.g., dogs, foxes), 
while the definitive animals, to become infectious, they must eat the organs of an intermediate 
animal that contains the valid cysts.
3. The parasitism establishment
Generally, selective pressure between host and parasite (parasitism relationship) provides 
chance for coevolution [21, 22]. A constant adaptation occurs in both populations due to an 
accumulation of the genetic changes that results in the development of new parasitic strate-
gies and new host defenses [21].
Parasites with complex life cycles often behave differently in their intermediate and definitive 
hosts [1, 23]. Echinococcus species presents strongly affected its intermediate hosts (moose or 
and small mammals, and rodents) due to high virulence but low virulence in the definitive 
hosts (such as wolf, fox, or dog). The strong effect makes the intermediate hosts to be more 
severe sick and easily be captured/hunted by the carnivorous animals [9, 18], thus, benefit 
parasitic life-cycle and increase transmission dynamics.
The relationship between Echinococcus species and their intermediate hosts leads to the neces-
sity for the pathogen to have the virulent alleles to infect the organism and for the host to 
have the resistant alleles to survive parasitism. Variation in the pathogenicity of strains/spe-
cies of Echinococcus is well known to influence the prognosis in patients with echinococcosis 
[23]. Increasing epidemiological evidence suggests that certain strains of E. granulosus (such 
as those adapted to horses and pigs) may not be commonly infective to humans [1], and 
the transmission of parasite strain differs (genetically) geographically and host-adaptively 
[24]. Therefore, estimates of gene flow between populations in different intermediate hosts 
or geographic areas can have valuable epidemiological applications [1, 11]. In the genomes 
of cestodes, considerable gene gain and gene loss associated with the adaptation to parasit-
ism has been found in recent genome parasitic programs [21, 22]. Although, the different 
morphologies of their metacestode stages caused by E. multilocularis and E. granulosus are 
clinically often regarded as “distinctly different entities” [25], they are highly similar concern-
ing gene structure and gene content [22]. Salient differences were so far only observed in the 
Echinococcus-specific apomucin gene family [21]. This is presumably associated with one of 
the few clear morphological differences between two species of E. multilocularis and E. granu­
losus, the thickness of the laminated layer, since the apomucin gene family encodes important 
components of this structure [26].
4. Interaction between Echinococcal parasites and their hosts
During echinococcosis infections (including AE and CE), the distinguishing feature of the 
host-parasite interaction is that chronic infection coexists with detectable humoral and cellular 
responses against the parasite [27]. It is well known that the Echinococcus species can actively 
interact with host’s both innate and acquired immune systems to maintain their  survival 
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with successful evasion from host’s immune attacks [28]. The disease spectrum is clearly 
dependent on the genetic background of the host, as well as on the acquired disturbances of 
Th1-related immunity [29], such as pregnancy [30], malnutrition [4], severe stress due to work 
or life [4], coinfection (e.g., HIV) [31, 32], or using immune-suppressing drugs [4, 28]; thus, this 
kind of circumstances can provide an opportunity to allow the pathogen invading. Human AE 
appears to be an example of “opportunistic infection”, when you make your immunity capa-
bility weakness [28, 30]. The genetic constitution of both hosts and pathogens is involved, host 
genes controlling resistance or susceptibility to infection, genes of the pathogen determining 
characters such as virulence [23].
In order to establish a successful infection, parasite releases molecules that directly modu-
late the host immune responses favoring and perpetuating parasite survival in the host [33]. 
Recent experimental evidence suggests that parasites can not only evade immune responses 
actively but also exploit the hormonal microenvironment within the host to favor their estab-
lishment and growth [34]. Hormonal host parasite cross communication facilitated by the 
relatively close phylogenetic relationship between E. multilocularis and its mammalian hosts, 
thus appears to be important in the pathology of AE [35]. E. multilocularis metacestode meta-
bolic pathway cascades can be activated by host’s cell signaling [13, 36], resulting in the larvae 
development [37]. Conversely, the larval Echinococcus can also influence their host immunity 
response and metabolic signaling mechanisms through the secretion of various molecules 
[24]. Therefore, immunomodulatory activities of Echinococcus and pathological consequences 
on the host’s tissues were attracted by many research concerns for decades [38].
The laminated layer could also play a role similar to that of the placenta at the materno-fetal 
interface [39]: ensuring parasite growth and infected tissue cell homeostasis while ensuring 
proper immune tolerance. Tolerance is essential to ensure growth and development of the 
larval stages of Echinococcus species in their hosts [27]. It has been recognized that a series of 
host-adapted species in the genus Echinococcus fits in nicely with observations on host range 
[1], life cycle, and transmission patterns in areas where echinococcosis is endemic [23]. The 
ability of hosts to regulate parasites through innate and adaptive immune responses is one of 
the most important determinants affecting levels of infection, both in the individual and the 
population [1]. Immunomodulation and, to some extents, immune tolerogenic role have been 
a great interest of researchers during echinococcosis infection both in human and in animal 
studies. Many reports have described the worms achieve to switch in the host's response by 
releasing molecules that share epitopes (and possibly functional activity) with host cytokines 
[40]. The high relevance for host parasite interaction mechanisms is also found that the pres-
ence of evolutionarily conserved signaling systems in Echinococcus, such as components of the 
epidermal growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor ß 
(TGF-ß), and insulin signal transduction cascades [40, 41], though the signaling systems in 
animals are also known to be primarily influenced by both factors of the genetic heritage and 
living environments [42].
The host-derived EGF is known to induce the Echinococcus mitogen-activated protein kinase 
(MAPK) cascade, probably through direct interaction with parasite EGF-receptors [13]. Para-
sitic components, and not only factors from host origin, were actually acting on hepatocyte 
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metabolic pathways. Recent report indicated that host insulin acts as a stimulant for parasite 
development within the host liver and that E. multilocularis senses the host hormone through an 
evolutionarily conserved insulin signaling pathway [13, 35].
Although both parasites and hosts benefit from the dynamic balance that grantees parasite-
induced damage to hosts at a reasonable level and in turn [42], to some extent, provide para-
sites nutrients, in some cases of human echinococcosis, spontaneous healing of the disease was 
observed [20, 27]. Such abortive cases are characterized by calcified parasite lesions suggesting 
the generation of immune responses which are able to limit parasite growth in humans [27].
5. Disease in animal hosts
A carnivore animal is the definitive host—where the adult worms live in the intestines; and 
almost any mammal, including humans, can be the intermediate host—where the worms 
form cysts in various organs for CE but mainly in liver for AE.
5.1. Infection in definitive hosts (mainly implication for dogs)
It is much more difficult to tell when a dog is infected with Echinococcus compared to other 
tapeworms such as Taenia or Dipylidium [16, 17]. An adult Echinococcus species is tiny—only a 
few millimeters long. Dog infection generally does not show any signs of illness at all even 
though the hundreds or thousands of tapeworms live in its intestine. Despite the difficult dif-
ferentiation of the eggs between Echinococcus and Taenia species under microscopy through 
fecal examinations [16, 17], the diagnosis of dog infection is an important and useful through 
dog-copro-DNA assays [16, 17, 43]. So, dog fecal examinations should be performed regularly.
5.2. Infections in intermediate animal hosts
For AE: the primary metacestodes are found in rodent’s liver. The germinal membrane of 
E. multilocularis proliferates externally, rather than internally, to form a multilocular struc-
ture with many small cysts. These vesicles are usually 1–10 mm in diameter. Hundreds to 
thousands of protoscolices develop from the germinal membrane in some animal interme-
diate hosts (small mammals). These multilocular cysts have semisolid matrix and resemble 
malignant tumors. The center of lesion may be necrotic. The lesion can completely infiltrate 
an organ, and spread to other organs and tissues nearby. The cysts can also metastasize to 
distant sites. Although, the tumor-like cysts can kill rodents within a few weeks of infection, 
this parasite has recently evolved into an experimental model system by use of rodent species 
to study larval cestode development and associated host-parasite interaction mechanisms.
For CE: the intermediate hosts include a large number of domesticated and wild animals, 
particularly herbivores. The rate of development varies with the intermediate host and spe-
cies of parasite, but the cysts usually grow slowly. Their diameter generally increases from 
less than 1 to 5 cm every year. The parasitic cyst comprises of two walls of an outer laminated 
membrane and an inner membrane called the germinal layer. All the brood capsules can be 
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produced from the germinal membrane. If the cyst contains protoscolices, it will be named as 
fertility cyst. Some cysts are sterile, since protoscolices are not produced or killed by bacterial 
infection. The percentage of sterile cysts varies with the different intermediate host and its 
susceptibility to a particular strain/species of parasite. The cysts in livestock also seem to be 
asymptomatic, probably due to the relatively short lifespan of these animals. Because the cyst 
grows slowly and the symptoms can only appear until its size can effect on adjacent tissues 
and organs. Occasionally, symptoms have been reported in sheep [5]. But mostly the infected 
livestock shows poor growth, weakness, and lameness. Therefore, the economic loss assess-
ment modeling due to livestock infections (mainly in sheep) has attracted some extensive 
attentions in endemic regions and countries worldwide.
6. Disease in humans
Epidemiological studies have demonstrated that the majority of human individuals exposed 
to infection with Echinococcus spp. eggs exhibit resistance to disease as shown by either sero-
conversion to parasite specific antigens or the presence of “dying out” or “aborted metaces-
todes” [4]. Seroconversion proving infection, but lack of any lesion indicating the failure of 
the parasite to establish and further develop within human tissues (mainly in liver) or resis-
tance as shown by the presence of fully calcified lesion [44]; while the developing parasite can 
be partially controlled by host immunity in those susceptibility individuals where infection 
leads to disease, as found in the AE and CE patients who experience clinical signs and symp-
toms approximately 5–15 years after infection [20, 30].
If untreated or uncontrolled, the hyper proliferation of the metacestode due to an impaired 
immune response could be resulted by immune modulation of host immunity toward energy 
that can be triggered by parasite metabolites [38], and/or be resulted by additional clinical 
conditions, such as AIDS or any other reason to induce the immune deficiencies [20, 27, 30]. 
The disease often starts without symptoms, and this may last for years. The symptoms and 
signs can occur depend on the lesion location and size for CE. While, AE usually begins in the 
liver but can spread to other parts of the body.
Cystic echinococcosis (CE) can cause very severe symptoms, if the cyst bursts (e.g., from sud-
den trauma) or even fatal. The released protoscolices can spread the parasite to other parts of 
the body to form many new cysts [20].
Alveolar echinocococcis (AE) ranges in size from a sesame seed to a large melon [45]. Although, 
the mass lesions grow slowly, the tumor-like growth manner tends to invade neighbor organs 
or tissues, making treatment very difficult [30].
Fibrosis is an important component of the pathophysiology of each disease caused by Echi­
nococcus species. However, this role differs markedly in CE and AE. In CE, the rapidly estab-
lished periparasitic fibrosis surrounding the laminated layer contributes to the unicystic 
feature of the disease and to limit cyst growth [46]. In AE, the slow fibrogenesis in an extensive 
and partially unsuccessful periparasitic granuloma does not prevent germinal layer budding. 
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In the long term, it eventually leads to a dense and irreversible fibrosis, responsible for the 
main complications of the diseases, such as bile duct, vessel obstruction, and secondary biliary 
cirrhosis [47–49].
7. Human disease diagnosis
Echinococcal lesions may grow for years, depending on their location, without causing any 
signs of illness in people [4]. The signs of illness do occur in late stages of diseases, such as 
abdominal pain and jaundice due to obstruction of bile ducts (in liver), chest pain and diffi-
culty in breathing (in lungs) [4], neurological signs, and seizures (in brain) [30]. Cysts/lesions 
are sometimes found occasionally when tests are performed for other reasons [4]. Generally, 
the clinical symptoms and image presentations, e.g., radiographs, ultrasound, CT, or MRI, 
need to combine the evidences from a blood test for antibodies to the parasite or biopsy for 
histopathological examination or PCR assay to confirm the diagnosis [4]. Screening individu-
als living in high-risk areas by ultrasound and serological investigation [44] can catch the 
infection early and can make treatment much easier and more effective [44].
Therefore, diagnosis requires a combination of tools that involve imaging, histopathology, or 
nucleic acid detection, and serology. The ultrasound though computer tomography (CT) or 
magnetic resonance imaging (MRI) may be used commonly. Serology methods for antibodies 
against the parasite detection can be some certain supplemental tool for imaging/clinical diag-
nosis. The histopathology or nucleic acid using biopsy after invading methods could provide 
the final confirmation [4, 20].
8. Management of echinococcosis in human
The growth of larva of Echinococcus spp. and the proliferation of the larva are similar to a slow-
growing tumor. If the lesion occurs in liver, it can damage liver function. Sometimes, it is dif-
ficult to differentiate it from liver cancer because of invasion to biliary and vascular tissue of the 
liver [50]. Early diagnosis and radical surgery provide the best chance for treatment and cure. 
Although, treatment of AE is less effective than treatment of CE, the general approach for both 
types of echinococcosis treatment remains to be surgery with the purpose of complete resection 
of infected parts of involved organs [4]. Antiparasitic drugs cannot kill cysts if the lesions have 
already established. However, if untreated, patient survival time is very limited. Therefore, 
early detection and treatment are important ways to improve patients' survival [4, 20].
Although treatment of cystic echinococcosis by surgery to remove the hydatid cyst was always a 
risk that the cyst would burst during the procedure, resulting in a very severe, even fatal reaction 
in the patient to the spilled fluid, drug therapy alone is usually not enough to eliminate cysts, 
but it can help reduce lesion size and operation risks. More recently, treatment with antiparasitic 
drugs and drainage of the fluid from the cyst using a needle has been used to treat the disease 
in certain cases without surgery. Briefly, with proper care, 96–98% of CE patients survive [20].
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9. Echinococcus species infective risk to humans
The risk of infection with E. granulosus or E. multilocularis to humans from most pets is very 
low, but it is higher risks for those residents living in endemic areas. Their work or recreational 
activities involve direct contact with contaminated water, soil, and their dogs for a long time or 
life time [10]. Those dogs may allow to roam, hunt, and eat raw tissues from potentially infected 
animals (e.g., rodents, rabbits, sheep, moose) [8].
The risks for the susceptible of infection with Echinococcus spp. can occur in those peoples 
with immune-compromised conditions (e.g., HIV/AIDS patients, transplant recipients, can-
cer patients) or with other complications because their immune systems cannot fight infec-
tions efficiently [20]. Mostly, ingestion of Echinococcal eggs occurred in early ages, if they have 
chance to contact with contaminated environments, but the disease may appear until they are 
adults [44].
10. Prevention and control program
Dogs if allowed to enter Echinococcus-free areas from potential endemic areas need to be 
treated with anthelmintic agents (e.g., Praziquantel). Routine inspection of the potential para-
sitic intermediate host animals before permitting for importing could also prevent the para-
site into a country [15].
In endemic areas, dogs should not be allowed to eat the carcasses, particularly the viscera of 
potential intermediate hosts. Dogs should also be kept from hunting wild rodents and small 
mammals [6]. Regular examination and treatment of dogs [8] can decrease echinococcosis in 
domesticated livestock [14].
Prevention of Echinococcus species spreading is by treating dogs that may carry the disease 
and vaccination of sheep. Health education programs focused on echinococcosis and its 
agents, and improvement of the water sanitation attempt to target poor economic living con-
dition and poor drinking water sources. Educational material should include information 
about proper disposal of sheep viscera in abattoirs and proximity to dogs and sources of 
transmission [15].
11. Parasitism perspective applications
11.1. Treatment parasitic infections
In the absence of fully effective antiparasitic chemotherapy for AE and CE, modulation of 
the host's immune response could be envisaged to fight against the parasite and to prevent 
the disease and/or its complications such as using IFN-a2a immunological treatment [28] 
and some parasitic antigens as potential vaccination to prevent disease occurrence such as 
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using Em14-3-3, Em 95, EMY162, and EmTetraspanin [24]. Additionally, current picture on 
Echinococcus signaling systems will be given and the potential to exploit these pathways as 
targets for antiparasitic chemotherapy [51].
11.2. Using parasite productions for cancer treatment
The presence of Tn antigen in larval and adult tissues of E. granulosus was reported [52], this 
finding is interested in cancer-associated mucin-type because this parasite produced peptides 
can act on the nonspecific natural killer cell to express cytokines that are effective agents 
against tumor growth; therefore, the family of Tn antigens might be useful targets for antitu-
mor immunotherapy [41, 53, 54]. These evidences may contribute to the design of tumor vac-
cines and open new horizons in the use of parasite-derived molecules that can fight against 
cancer [55, 56].
Cancer vaccination is an important and promising approach in cancer immunotherapy. 
Obstacles for clinical success may include immune tolerance to TAAs [57], the weak antigenic 
nature of TAAs, and active immune evasion mechanisms employed by progressing tumors [58]. 
Vaccination with TAAs coming from evolutionary distant organisms (such as E. granulosus) 
should be useful to override tolerance problems encountered with human TAA-based cancer 
therapeutic approaches [58].
11.3. Echinococcosis diagnosis
Additionally, the high level of the O-glycosylated Tn antigens generated from larvae of 
E. granulosus are found in the sera of the patients with cystic echinococcosis (CE), providing 
a pathway that a series of Tn antigens might be sort as a biomarker for this parasitic disease 
diagnosis, but the hypothesis needs more work to verify the clinical values regarding those 
antigens [59].
12. Conclusions
Overall, genus Echinococcus can be thought an example of successful adaptation to their hosts 
extensively. Taken advance of recent research outcomes, the parasite immunotherapy for 
human echinococcosis has been discussed widely by scientific literatures, but importantly, 
the advanced outcomes may also be interested in terms of using parasites' productions for 
treatment of other diseases, including cancer.
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